Saturday 17 October 2026
Export ZBH’s income statement to Excel — free account
Zimmer Biomet Holdings, Inc.
ZBH Healthcare Medical Devices
Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024. In the quarter to June 2026, revenue grew 4.80%, EPS grew 33.8%, free cash flow grew 13.1% and total debt fell 1.23%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five.
95.06
0.68
+0.72%
Follow ZBH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
24.26 | 25.19 | 23.36 | 20.85 |
P/S ratio |
2.44 | 2.16 | 2.10 | 1.94 | |
P/FCF ratio |
19.29 | 16.53 | 17.49 | 15.96 | |
P/Operating CF |
46.60 | 34.41 | 49.06 | 36.95 | |
P/B ratio |
1.53 | 1.40 | 1.39 | 1.31 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.29 | 3.00 | 2.93 | 2.78 | |
EV/EBITDA |
10.94 | 11.28 | 10.78 | 10.21 | |
EV/Operating CF |
15.62 | 14.57 | 14.75 | 13.55 | |
EV/FCF |
26.04 | 22.96 | 24.48 | 22.78 | |
Quick Ratio |
1.20 | 0.89 | 0.75 | 0.72 | |
Current Ratio |
2.43 | 1.98 | 1.73 | 1.69 | |
Net Debt/EBITDA |
10.74 | 15.80 | 10.96 | 11.84 | |
Debt/Assets |
34.54% | 32.56% | 32.88% | 32.81% | |
Debt/Equity |
0.64 | 0.59 | 0.59 | 0.59 | |
Asset Turnover |
0.35 | 0.37 | 0.37 | 0.37 | |
Operating CF/Net income |
1.81 | 3.71 | 1.51 | 2.26 | |
Capex/Depreciation |
(0.53) | (0.71) | (0.56) | (0.75) | |
Interest Coverage |
4.66 | 2.15 | 5.42 | 4.47 | |
Research and Development Expense of Revenue |
5.79% | 5.29% | 4.96% | 4.81% | |
Selling, General and Administrative Expense of Revenue |
40.54% | 38.87% | 40.73% | 41.31% | |
Intangible Assets out of Total Assets |
0.61 | 0.64 | 0.64 | 0.63 | |
Share Based Compensation of Revenue |
1.26% | 1.07% | 1.16% | 1.13% | |
Graham Net Nets |
(0.25) | (0.30) | (0.29) | (0.31) | |
Graham Number |
76.73 | 71.79 | 75.25 | 78.15 | |
Earnings Yield |
4.12% | 3.97% | 4.28% | 4.80% | |
Free Cash Flow Yield |
5.18% | 6.05% | 5.72% | 6.26% | |
Revenue per Share |
10.10 | 11.33 | 10.70 | 11.33 | |
Operating CF per Share |
2.11 | 2.61 | 1.84 | 2.33 | |
Capex per Share |
(0.76) | (1.02) | (0.78) | (1.05) | |
Free Cash Flow per Share |
1.35 | 1.60 | 1.06 | 1.28 | |
Cash per Share |
6.53 | 2.99 | 2.18 | 2.13 | |
Shareholders Equity per Share |
64.44 | 64.17 | 65.03 | 65.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
64.44 | 64.17 | 65.03 | 65.73 | |
Free Cash Flow |
267.70 | 315.90 | 206.90 | 246.00 | |
Working Capital |
3,432.00 | 2,536.20 | 2,098.20 | 2,083.20 | |
Capital Expenditures |
(151.00) | (201.50) | (152.50) | (201.80) | |
Net Current Asset Value |
(4,887.10) | (5,266.10) | (5,077.50) | (5,068.60) | |
EV/EBIT |
19.76 | 22.52 | 20.93 | 19.60 | |
Capex to Sales |
0.08 | 0.09 | 0.07 | 0.09 | |
Price to Operating Income |
14.64 | 16.21 | 14.96 | 13.73 | |
| Other line items | |||||
Average Receivables |
1,539.90 | 1,592.55 | 1,631.00 | 1,690.40 | |
Average Payables |
318.85 | 248.80 | 331.25 | 350.55 | |
Average Inventory |
2,426.20 | 2,260.85 | 2,245.50 | 2,362.25 | |
Average Assets |
22,604.15 | 22,228.50 | 22,452.75 | 22,831.45 | |
Average Common Equity |
12,574.60 | 12,591.00 | 12,542.65 | 12,583.45 |
Columns are period end dates